Production (Stage)
Apellis Pharmaceuticals, Inc.
APLS
$17.44
-$0.34-1.91%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 166.80M | 212.53M | 196.83M | 199.69M | 172.33M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 166.80M | 212.53M | 196.83M | 199.69M | 172.33M |
| Cost of Revenue | 120.78M | 117.21M | 122.13M | 101.05M | 104.91M |
| Gross Profit | 46.02M | 95.32M | 74.70M | 98.64M | 67.42M |
| SG&A Expenses | 129.35M | 121.48M | 121.98M | 128.08M | 129.51M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 250.13M | 238.69M | 244.11M | 229.13M | 234.42M |
| Operating Income | -83.33M | -26.16M | -47.28M | -29.44M | -62.09M |
| Income Before Tax | -91.88M | -36.07M | -56.85M | -37.54M | -66.25M |
| Income Tax Expenses | 341.00K | 286.00K | 592.00K | 114.00K | 170.00K |
| Earnings from Continuing Operations | -92.23M | -36.35M | -57.45M | -37.66M | -66.42M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -92.23M | -36.35M | -57.45M | -37.66M | -66.42M |
| EBIT | -83.33M | -26.16M | -47.28M | -29.44M | -62.09M |
| EBITDA | -82.88M | -25.72M | -46.82M | -28.99M | -61.65M |
| EPS Basic | -0.74 | -0.29 | -0.46 | -0.30 | -0.54 |
| Normalized Basic EPS | -0.46 | -0.18 | -0.29 | -0.18 | -0.34 |
| EPS Diluted | -0.74 | -0.29 | -0.46 | -0.30 | -0.54 |
| Normalized Diluted EPS | -0.46 | -0.18 | -0.29 | -0.18 | -0.34 |
| Average Basic Shares Outstanding | 125.45M | 124.52M | 124.23M | 123.90M | 122.96M |
| Average Diluted Shares Outstanding | 125.45M | 124.52M | 124.23M | 123.90M | 122.96M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |